VJOncology is committed to improving our service to you

ESMO 2019 | Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort

VJOncology is committed to improving our service to you

Shirish Gadgeel

Shirish Gadgeel, University of Michigan, Ann Arbor, MI, gives an update on the ALK+ cohort of the Blood First Assay Screening Trial (BFAST) in patients (pts) with treatment-naïve non-small cell lung cancer (NSCLC), comparing the results to the previous ALEX study (NCT02075840). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter